TVTX
Travere Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 6 ▼ Travere Therapeutics insiders executed a significant cluster of open…
- Apr 13 ▲ Travere Therapeutics (TVTX) announced FDA approval of FILSPARI (spar…
- Apr 13 FDA decision: PDUFA: TVTX, FILSPARI in Focal Segmental Glomerulosclerosi…
- Apr 14 ▼ Four executives at Travere Therapeutics sold $2.15M in shares over t…
- Apr 15 ▼ Five executives at Travere Therapeutics, including the CEO, CFO, and…
- May 1 ▼ Multiple Travere Therapeutics insiders, including the CEO, CFO, and…
- Jun 2 ▲ Travere Therapeutics entered into a license and collaboration agreem…
- Jul 1 HSR Early Termination: Travere Therapeutics, Inc.; Everest…
- Sep 15 to Sep 17 ▼ 3 days of insider sells: $52.6M by 7 insiders, avg $63.27
- Oct 15 ▼ 1 insider sell $13.1M at $53.82
- Nov 2 ▼ Earnings: TVTX Q3 2026 Earnings: EPS $-0.55 (-846.6% vs est)
- Nov 2 ▲ Travere Therapeutics reported Q3 2026 FILSPARI net product sales of…
Signal stack
Where each data set points today.
- InsidersBEARISH
7 insiders sold $65.8M.
- InstitutionsBULLISH
Q3 2026: 44 added (2 new), 21 trimmed or exited. Largest new: Fuller & Thaler Asset Management, $38.9M, Dimensional Fund Advisors $20.2M.
- AnalystsBULLISH
19 of 21 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest −12.4% to 9.56M shares. 4.7 days to cover, ≈10.0% of shares.
- TrendDOWNTREND
11% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | $179.0M |
| Assenagon Asset Management S.A. | DOUBLED | $67.4M |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | $63.5M |
| MARSHALL WACE, LLP | TRIM | $57.6M |
| Russell Investments Group, Ltd. | ADD | $45.8M |
| FULLER & THALER ASSET MANAGEMENT, INC. | NEW | $38.9M |
| JPMORGAN CHASE & CO | ADD | $23.5M |
| FIRST TRUST ADVISORS LP | ADD | $22.0M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
21 analystsPrice is below the lowest target. Median implies +48%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 6, 2026 | JP Morgan MAINTAIN | Overweight |
| Nov 5, 2026 | Leerink Partners MAINTAIN | Outperform |
| Nov 4, 2026 | Canaccord Genuity MAINTAIN | Buy |
| Nov 4, 2026 | Guggenheim MAINTAIN | Buy |
| Sep 24, 2026 | Guggenheim MAINTAIN | Buy |
| Sep 22, 2026 | Wedbush REITERATE | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Dube Eric M CHIEF EXECUTIVE OFFICER Oct 15, 2026 | EXERCISE | $1.2M |
Dube Eric M CHIEF EXECUTIVE OFFICER Oct 15, 2026 | EXERCISE | $1.8M |
Dube Eric M CHIEF EXECUTIVE OFFICER Oct 15, 2026 | SELL | $6.8M |
Dube Eric M CHIEF EXECUTIVE OFFICER Oct 15, 2026 | SELL | $2.0M |
Dube Eric M CHIEF EXECUTIVE OFFICER Oct 15, 2026 | SELL | $4.3M |
Dube Eric M CHIEF EXECUTIVE OFFICER Sep 17, 2026 | SELL | $6.6M |
Dube Eric M CHIEF EXECUTIVE OFFICER Sep 17, 2026 | EXERCISE | $2.5M |
Dube Eric M CHIEF EXECUTIVE OFFICER Sep 17, 2026 | SELL | $441.8K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | $1.05 | $0.80–$1.27 | +4.0% | $254.7M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
21 filings · 5 bullish · 5 bearish · 11 neutral- NEUTRAL SC 13G/ANov 16, 2026
Bank of America Corp filed an amended Schedule 13G reporting a 7.1% passive stake in Travere Therapeutics as of September 30, 2026, up from a prior filing. This is a routine passive stake update by a large financial institution with no change in investment intent.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 5, 2026
FMR LLC (Fidelity) filed an amended Schedule 13G reporting a 6.1% passive stake in Travere…
Fidelity's increased passive stake to 6.1% aligns with the strong FILSPARI revenue trajectory reported on November 2. Monitor for any future conversion to an active 13D filing, which would signal a…
- BULLISH INST-CLUSTERNov 3, 2026
Seven institutional investors increased their TVTX positions in Q3 2026, with aggregate buying of…
The institutional cluster aligns with the strong FILSPARI revenue beat reported yesterday, but the 13F data is already 5 weeks stale. Watch for any insider buying or additional 13F filings from…
- BULLISH 8-KNov 2, 2026
Travere Therapeutics reported Q3 2026 FILSPARI net product sales of $200.2M, up 120% YoY, and…
The 120% FILSPARI growth and 1,932 PSFs confirm strong commercial execution in IgAN and early FSGS launch momentum. The $113.1M IPRD charge for civorebrutinib is a one-time non-cash item; watch for…
All TVTX filing & press-release reports (21)
- SC 13G/A reportNov 16, 2026
- SC 13G/A reportNov 5, 2026
- INST-CLUSTER reportNov 3, 2026
- 8-K reportNov 2, 2026
- CLUSTER reportSep 17, 2026
- 8-K reportJul 9, 2026
- 8-K reportJun 16, 2026
- CLUSTER reportJun 16, 2026
- 144 reportJun 12, 2026
- 8-K reportJun 2, 2026
- 144 reportMay 15, 2026
- CLUSTER reportMay 1, 2026
- 144 reportMay 5, 2026
- 144 reportMay 4, 2026
- CLUSTER reportApr 15, 2026
- CLUSTER reportApr 14, 2026
- CLUSTER reportApr 6, 2026
- 144 reportApr 14, 2026
- 8-K reportApr 13, 2026
- 144 reportApr 1, 2026
- INST-CLUSTER reportFeb 28, 2026